514 results on '"Swinnen, Lode J."'
Search Results
52. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
53. A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)
54. Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma
55. An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis
56. Organ transplant-related lymphoma
57. Immune-cell treatment of Epstein–Barr-virus-associated lymphoproliferative disorders
58. Outcomes of Kidney Transplantation in HIV-Infected Recipients
59. Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use
60. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
61. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma
62. Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
63. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
64. Posttransplant Lymphoproliferative Disorder
65. Contributors
66. Epstein-Barr Viral Load as a Marker of Lymphoma in AIDS Patients
67. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors
68. Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model
69. Simian Virus 40 Is Present in Most United States Human Mesotheliomas, but It Is Rarely Present in Non-Hodgkin's Lymphoma*
70. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
71. Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients
72. PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
73. Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS
74. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
75. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma
76. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
77. Post-Transplantation Lymphoproliferative Disorder and OKT3
78. Solid Organ Transplantation in Selected Patients With a History of Lymphoma: Has the Time Come?
79. Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)
80. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
81. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
82. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide
83. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015: Clinical Practice Guidelines in Oncology
84. Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology
85. Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
86. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
87. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
88. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial
89. The Use of Post-Transplantation Cyclophosphamide after Myeloablative, HLA-Matched Allogeneic Bone Marrow Transplantation Minimizes the Need for Additional Immunosuppression
90. Diffuse Large B-Cell Lymphoma Version 1.2016
91. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
92. Post-transplant Lymphoproliferative Disorders: Implications for Acquired Immunodeficiency Syndrome-Associated Malignancies
93. Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial
94. Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]
95. Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process
96. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide
97. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
98. Central Nervous System Cancers, Version 1.2015
99. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage
100. Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.